Christos Nousias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christos Nousias has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- François Boutin
University of Montpellier
2 shared publications - Gaoussou Sanou
IMGT®, IGH, Univ Montpellier, CNRS, Montpellier, France
2 shared publications Imene Maalem
IMGT®, IGH, Univ Montpellier, CNRS
2 shared publications- Marie-Paule Lefranc
IMGT®, The International ImMunoGeneTics Information System® (IMGT), Laboratoire d’ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Université de Montpellier (UM), Centre National de la Recherche Scientifique (CNRS), UMR 9002 CNRS-UM, 141 Rue de la Cardonille, CEDEX 5, 34396 Montpellier, France
2 shared publications - Patrice Duroux
IMGT®, the international ImMunoGeneTics information system® Laboratoire d'ImmunoGénétique Moléculaire LIGM Université Montpellier 2
2 shared publications - Sofia Kossida
IMGT®, IGH, Univ Montpellier, CNRS, Montpellier, France
2 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2594260
Identification of engineered IMGT Fc variants in IMGT/mAb-DB, a database of therapeutic antibodies and fusion proteins
Monoclonal antibodies (mAbs) and fusion proteins for immune applications (FPIA) play a crucial role in treating autoimmune diseases and cancers by targeting cell-surface proteins and triggering multiple immune mechanisms. These functions are mediated by the crystallizable fragment (Fc) region of mAbs and fusion proteins, whose interaction with Fc gamma receptors (FcγRs) can be modulated through Fc amino acid (AA) engineering. To aid research in this area, we developed the IMGT/FcVariantsExplorer tool (https://www.imgt.org/fcvariantsexplorer/) to identify engineered AA changes or variants within the Fc region in mAb and fusion proteins sequences from IMGT/2Dstructure-DB, the AA sequence database of IMGT®, the international ImMunoGeneTics information system®. We used the IMGT® nomenclature of engineered Fc variants involved in antibody effector properties and formats, applying a standardized classification in five categories: 'Effector,' 'Half-life,' 'Physicochemical properties,' 'Structure,' and 'Hybrid.' We analyzed sequences from 1,107 mAbs and fusion proteins, identifying 483 entries with Fc AA changes, resulting in 211 unique Fc variants in the dataset. We also used web scraping to retrieve associated biological data from literature. All data have been integrated into IMGT/mAb-DB, with links to sequences in IMGT/2Dstructure-DB, enabling users to query Fc variants by their 'Category' or 'Effect.' This curated dataset reveals key trends in antibody engineering.
- 27 November 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2594260
Open AccessIdentification of engineered IMGT Fc variants in IMGT/mAb-DB, a database of therapeutic antibodies and fusion proteins
Monoclonal antibodies (mAbs) and fusion proteins for immune applications (FPIA) play a crucial role in treating autoimmune diseases and cancers by targeting cell-surface proteins and triggering multiple immune mechanisms. These functions are mediated by the crystallizable fragment (Fc) region of mAbs and fusion proteins, whose interaction with Fc gamma receptors (FcγRs) can be modulated through Fc amino acid (AA) engineering. To aid research in this area, we developed the IMGT/FcVariantsExplorer tool (https://www.imgt.org/fcvariantsexplorer/) to identify engineered AA changes or variants within the Fc region in mAb and fusion proteins sequences from IMGT/2Dstructure-DB, the AA sequence database of IMGT®, the international ImMunoGeneTics information system®. We used the IMGT® nomenclature of engineered Fc variants involved in antibody effector properties and formats, applying a standardized classification in five categories: 'Effector,' 'Half-life,' 'Physicochemical properties,' 'Structure,' and 'Hybrid.' We analyzed sequences from 1,107 mAbs and fusion proteins, identifying 483 entries with Fc AA changes, resulting in 211 unique Fc variants in the dataset. We also used web scraping to retrieve associated biological data from literature. All data have been integrated into IMGT/mAb-DB, with links to sequences in IMGT/2Dstructure-DB, enabling users to query Fc variants by their 'Category' or 'Effect.' This curated dataset reveals key trends in antibody engineering.
- Open Access
Identification of Engineered IMGT Fc Variants in IMGT/mAb-DB Therapeutic Antibodies and Fusion proteins
Monoclonal antibodies (mAbs) and fusion proteins for immune applications (FPIA) play a crucial role in treating autoimmune diseases and cancers by targeting cell-surface proteins and triggering multiple immune mechanisms. These functions are mediated by the fragment crystallizable (Fc) region of mAbs and fusion proteins, whose interaction with Fc gamma receptors (FcγRs) can be modulated through Fc amino acid (AA) engineering. To address this, we developed the IMGT/FcVariantsExplorer tool ( https://www.imgt.org/fcvariantsexplorer/ ) to identify AA changes within the Fc region in mAb and fusion proteins sequences from IMGT/2Dstructure-DB, the AA sequence database of IMGT®, the international ImMunoGeneTics information system®. We used the IMGT® nomenclature of engineered Fc variants involved in antibody effector properties and formats, applying a standardized classification in five categories: ‘Effector’, ‘Half-life’, ‘Physicochemical properties’, ‘Structure’, and ‘Hybrid’. We analyzed sequences of 1,107 mAbs and fusion proteins, identifying 483 entries with Fc AA changes, resulting in 211 unique Fc variants in the dataset. We also used web scraping to retrieve associated biological data from literature. All data have been integrated into IMGT/mAb-DB, with links to sequences in IMGT/2Dstructure-DB, enabling users to query Fc variants by their ‘Category’ or ‘Effect’. This curated dataset reveals key trends in antibody engineering.
Open AccessIdentification of Engineered IMGT Fc Variants in IMGT/mAb-DB Therapeutic Antibodies and Fusion proteins
Monoclonal antibodies (mAbs) and fusion proteins for immune applications (FPIA) play a crucial role in treating autoimmune diseases and cancers by targeting cell-surface proteins and triggering multiple immune mechanisms. These functions are mediated by the fragment crystallizable (Fc) region of mAbs and fusion proteins, whose interaction with Fc gamma receptors (FcγRs) can be modulated through Fc amino acid (AA) engineering. To address this, we developed the IMGT/FcVariantsExplorer tool ( https://www.imgt.org/fcvariantsexplorer/ ) to identify AA changes within the Fc region in mAb and fusion proteins sequences from IMGT/2Dstructure-DB, the AA sequence database of IMGT®, the international ImMunoGeneTics information system®. We used the IMGT® nomenclature of engineered Fc variants involved in antibody effector properties and formats, applying a standardized classification in five categories: ‘Effector’, ‘Half-life’, ‘Physicochemical properties’, ‘Structure’, and ‘Hybrid’. We analyzed sequences of 1,107 mAbs and fusion proteins, identifying 483 entries with Fc AA changes, resulting in 211 unique Fc variants in the dataset. We also used web scraping to retrieve associated biological data from literature. All data have been integrated into IMGT/mAb-DB, with links to sequences in IMGT/2Dstructure-DB, enabling users to query Fc variants by their ‘Category’ or ‘Effect’. This curated dataset reveals key trends in antibody engineering.